Aric Rogers in his lab at the MDI Biological Laboratory PHOTO COURTESY OF THE MDI BIOLOGICAL LABORATORY

Grant to support longevity research



BAR HARBOR — Aric Rogers of the MDI Biological Laboratory has received a grant of $455,000 over two years from the National Institute on Aging, one of the institutes of the National Institutes of Health, for research on the cellular mechanisms governing longevity.

The grant will allow Rogers to delve more deeply into his discovery that nonsense-medicated decay (NMD), a regulatory mechanism that governs a wide array of genetic functions, also plays a critical role in extending longevity under conditions of dietary restriction.

Dietary restriction (DR), which typically involves a dramatic reduction in calories without malnutrition, has been known for many years to extend lifespan and delay or reduce the risk of many age-related diseases in a wide range of species, from single-celled yeasts to primates.

“We have found that the restriction and redirection of NMD has a major influence on the extension of lifespan under conditions of [dietary restriction],” Rogers said. “The takeaway is that the NMD pathway is a requirement for the increase in longevity that occurs with [dietary restriction]; if it doesn’t work properly, lifespan extension is forfeited.”

The role of dietary restriction in prolonging healthy lifespan has set scientists on a quest to identify drug candidates called “DR mimetics” that mimic the effects of dietary restriction on longevity. The use of such drugs would allow patients to experience the health- and lifespan-enhancing effects of DR without the difficulty of adhering to a diet that drastically cuts calories.

The significance of Rogers’ discovery lies with the fact that the pharmaceutical industry is already intensely focused on developing drugs to manipulate NMD because of its role in many genetic disorders and many forms of cancer. Rogers’ discovery thus raises the possibility that these drugs could be repurposed to extend healthy lifespan.

“The fact that NMD is already a target for therapeutic manipulation is good news,” Rogers said. “Since drug candidates vary in their targets, effectiveness and the speed with which they move through the development process, an expanded pipeline increases the likelihood that life-extending therapies will soon become available.”

In the classical model, NMD functions as a quality-control mechanism by removing aberrant gene products that could result in the production of deleterious proteins. However, mutations can cause NMD to inappropriately target certain proteins, resulting in cancers and genetic disorders such as cystic fibrosis and hemophilia.

Rogers’ data suggest a revised model in which NMD functions like a control panel that helps an organism adapt to environmental stressors such as food scarcity by changing gene activity levels. Thus, drugs that target NMD could be used to trigger the adaptive responses normally associated with DR, bypassing the need for extreme dieting.

Since pharmaceutical companies are already developing drugs that inhibit or redirect NMD for use in the treatment of genetic disorders, Rogers’ discovery raises the possibility that some of these drugs could offer a “new realm” of DR mimetics.

Rogers works at the Kathryn W. Davis Center for Regenerative Biology and Medicine, where he studies aging in C. elegans, a nematode worm that is a popular model in aging research because it shares nearly half its genes with humans and because its short lifespan allows scientists to quickly assess the role of anti-aging interventions.